COA ↓

Product

COA Doc

SYN-2612

99.1% Purity SYN-2612 Research Grade HPLC Verified

CJC-1295 No Dac + Ipamorelin Stack

Synergistic GH Optimisation Complex · Research Grade

Select Strength — 10mg

$145.00

C₁₄₉H₂₄₄N₄₂O₄₂S / C₃₈H₄₉N₉O₅ MW: 3367.90 / 711.86 g/mol CAS: 863288-34-0 / 170851-70-4

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.1% / 99.3%

HPLC Purity

Lot Number SYN-2612-STK

Test Date March 2025

Labeled 5 mg each

Actual 5.02 / 5.01 mg

99.0% / 99.2%

HPLC Purity

Lot Number SYN-2611-STK

Test Date January 2025

Labeled 5 mg each

Actual 5.03 / 5.02 mg

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 Dual Receptor Mechanism

GHRH-R + GHSR-1a Synergy

CJC-1295 activates GHRH-R (the synthesis/release signal), while Ipamorelin activates GHSR-1a (the amplification signal that simultaneously inhibits somatostatin). This dual-pathway activation produces synergistic GH release.

CJC-1295 — GHRH-R Activated

Ipamorelin — GHSR-1a Activated

Somatostatin ↓ Inhibited

GH Pulse 5.8× baseline

🔬 Dual receptor activation removes both GH synthesis limitation (GHRH-R) and GH inhibition (somatostatin) simultaneously — producing a greater GH response than either pathway alone.

PMID 9671117 — Endocrinology

🎯 Ipamorelin Selectivity

Clean GHRP Profile — No Cortisol or Prolactin

Ipamorelin's GHSR-1a selectivity produces GH stimulation without the cortisol, prolactin, or ACTH elevation associated with other GHRP compounds — making it the preferred GHRP for research requiring isolated GH axis effects.

🔬 Ipamorelin is the only GHRP with published data showing significant GH elevation with zero cortisol or prolactin co-elevation at research concentrations.

PMID 9671117 — Endocrinology

⚡ Combined IGF-1 Elevation

Downstream Anabolic Signalling

The amplified GH pulses produced by the stack drive proportionally greater hepatic IGF-1 production via JAK2-STAT5, activating downstream anabolic signalling pathways in muscle, bone, and connective tissue cell cultures.

🔬 Combined GH pulse amplitude of 5.8× produces downstream IGF-1 elevation of 3.2× — significantly exceeding individual compound effects.

PMID 16352683 — J. Clin. Endocrinol. Metab.

5.8 ×

Synergistic GH Release vs. Individual Compounds

CJC-1295 (GHRH-R agonist) and Ipamorelin (GHSR-1a agonist) activate GH release through independent receptor systems. Combined, they produce a synergistic GH pulse significantly greater than either compound alone.

GH Release — Individual vs. Stack Comparison

Stack (combined) 5.8×

CJC-1295 alone 3.0×

Ipamorelin alone 2.8×

Untreated 1.0×

Source: In Vitro Pituitary Cell Culture, published data

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2612-STK

Specification	Value
CAS Number	863288-34-0 / 170851-70-4
Molecular Formula	C₁₄₉H₂₄₄N₄₂O₄₂S / C₃₈H₄₉N₉O₅
Molecular Weight	3367.90 / 711.86 g/mol
Purity (HPLC)	99.1%
Appearance	White lyophilised powder (dual-vial kit)
Solubility	Both: Soluble in water
Storage	−20°C long-term / 2–8°C short-term (store vials separately)
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

5.8 ×

Combined GH Release vs. Untreated Control

CJC + Ipamorelin 5.8×

CJC-1295 alone 3.0×

Ipamorelin alone 2.8×

Untreated 1.0×

Comparative Activity Profile

Stack CJC alone Ipa alone

Observed Adverse Indicators

Cytotoxicity (either compound)

None

Cortisol or prolactin elevation

None

Synergistic GH axis activation

Expected

Off-target receptor binding

None

⚠️ Theoretical Concern

Amplified GH Axis Stimulation

The synergistic combination produces substantially greater GH release than either compound alone. Researchers should account for this amplified downstream IGF-1 axis activity in experimental designs.

No cytotoxicity, genotoxicity, or mutagenicity for either compound in published in vitro studies
Ipamorelin produces no cortisol or prolactin elevation — the cleanest GHRP profile in published receptor data
Synergistic GH elevation is the expected and desired outcome of this stack — account for downstream IGF-1 in experimental design

CJC-1295 No Dac + Ipamorelin Stack

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

GHRH-R + GHSR-1a Synergy

Clean GHRP Profile — No Cortisol or Prolactin

Downstream Anabolic Signalling

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Amplified GH Axis Stimulation

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS